BlackRock’s Myriad Genetics MYGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$62.2M Buy
10,890,440
+2,000,796
+23% +$9.08M ﹤0.01% 2533
2026
Q1
$40M Sell
8,889,644
-6,414,206
-42% -$33.4M ﹤0.01% 2653
2025
Q4
$94.1M Buy
15,303,850
+424,423
+3% +$3.08M ﹤0.01% 2137
2025
Q3
$108M Sell
14,879,427
-192,832
-1% -$1.14M ﹤0.01% 2056
2025
Q2
$80M Sell
15,072,259
-385,917
-2% -$2.28M ﹤0.01% 2193
2025
Q1
$137M Sell
15,458,176
-449,417
-3% -$5.4M ﹤0.01% 1807
2024
Q4
$218M Buy
15,907,593
+465,254
+3% +$8.58M ﹤0.01% 1619
2024
Q3
$423M Buy
15,442,339
+291,533
+2% +$7.89M 0.01% 1192
2024
Q2
$371M Buy
15,150,806
+271,487
+2% +$5.96M 0.01% 1205
2024
Q1
$317M Buy
14,879,319
+220,970
+2% +$4.75M 0.01% 1327
2023
Q4
$281M Buy
14,658,349
+1,031,424
+8% +$17.8M 0.01% 1411
2023
Q3
$219M Sell
13,626,925
-477,679
-3% -$9.09M 0.01% 1473
2023
Q2
$327M Sell
14,104,604
-23,104
-0.2% -$504K 0.01% 1232
2023
Q1
$328M Sell
14,127,708
-228,391
-2% -$4.64M 0.01% 1205
2022
Q4
$208M Sell
14,356,099
-227,096
-2% -$4.23M 0.01% 1504
2022
Q3
$278M Sell
14,583,195
-175,205
-1% -$4.02M 0.01% 1228
2022
Q2
$268M Sell
14,758,400
-39,429
-0.3% -$819K 0.01% 1306
2022
Q1
$373M Buy
14,797,829
+113,042
+0.8% +$2.89M 0.01% 1190
2021
Q4
$405M Buy
14,684,787
+1,123,482
+8% +$32.5M 0.01% 1199
2021
Q3
$438M Sell
13,561,305
-42,365
-0.3% -$1.41M 0.01% 1090
2021
Q2
$416M Buy
13,603,670
+373,791
+3% +$10.8M 0.01% 1177
2021
Q1
$403M Buy
13,229,879
+727,959
+6% +$20.7M 0.01% 1200
2020
Q4
$247M Buy
12,501,920
+89,486
+0.7% +$1.45M 0.01% 1453
2020
Q3
$162M Sell
12,412,434
-219,989
-2% -$2.78M 0.01% 1559
2020
Q2
$143M Buy
12,632,423
+173,737
+1% +$2.47M 0.01% 1594
2020
Q1
$178M Sell
12,458,686
-293,433
-2% -$6.2M 0.01% 1251
2019
Q4
$347M Buy
12,752,119
+276,739
+2% +$7.61M 0.01% 1086
2019
Q3
$357M Sell
12,475,380
-59,966
-0.5% -$1.75M 0.02% 994
2019
Q2
$348M Buy
12,535,346
+509,214
+4% +$14.4M 0.01% 1026
2019
Q1
$399M Sell
12,026,132
-176,310
-1% -$5.37M 0.02% 893
2018
Q4
$355M Buy
12,202,442
+735,832
+6% +$26.5M 0.02% 872
2018
Q3
$527M Buy
11,466,610
+383,089
+3% +$17M 0.02% 730
2018
Q2
$414M Buy
11,083,521
+691,243
+7% +$23.3M 0.02% 859
2018
Q1
$307M Buy
10,392,278
+325,525
+3% +$11M 0.01% 1053
2017
Q4
$346M Buy
10,066,753
+150,003
+2% +$5.06M 0.02% 956
2017
Q3
$359M Buy
9,916,750
+467,223
+5% +$13.3M 0.02% 885
2017
Q2
$244M Sell
9,449,527
-92,357
-1% -$1.96M 0.01% 1130
2017
Q1
$183M Buy
9,541,884
+9,536,219
+168,336% +$169M 0.01% 1368
2016
Q4
$94K Sell
5,665
-10,750
-65% -$194K ﹤0.01% 2577
2016
Q3
$338K Sell
16,415
-1,232
-7% -$31.2K ﹤0.01% 1889
2016
Q2
$539K Buy
17,647
+12,932
+274% +$449K ﹤0.01% 1641
2016
Q1
$176K Buy
4,715
+2,604
+123% +$98.1K ﹤0.01% 1763
2015
Q4
$91K Buy
2,111
+164
+8% +$6.93K ﹤0.01% 1804
2015
Q3
$73K Buy
1,947
+28
+1% +$994 ﹤0.01% 1805
2015
Q2
$66K Sell
1,919
-151
-7% -$5.13K ﹤0.01% 1888
2015
Q1
$73K Hold
2,070
﹤0.01% 1837
2014
Q4
$71K Sell
2,070
-98
-5% -$3.48K ﹤0.01% 1826
2014
Q3
$83K Sell
2,168
-4,377
-67% -$163K ﹤0.01% 1762
2014
Q2
$255K Buy
6,545
+794
+14% +$29.5K ﹤0.01% 1445
2014
Q1
$196K Sell
5,751
-5,202
-47% -$161K ﹤0.01% 1553
2013
Q4
$230K Buy
10,953
+5,821
+113% +$147K ﹤0.01% 1566
2013
Q3
$121K Sell
5,132
-22,063
-81% -$627K ﹤0.01% 1617
2013
Q2
$730K Buy
+27,195
New +$788K ﹤0.01% 1129

Other funds holding MYGN

BlackRock's MYGN Position: Q2 2026 in Review

BlackRock increased its Myriad Genetics (MYGN) stake by 23% in Q2 2026, buying an estimated $9.08M and bringing the position to 10,890,440 shares worth $62.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2533.

BlackRock first reported a position in MYGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $527M in Q3 2018. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • BlackRock held 10,890,440 shares of Myriad Genetics worth $62.2M as of Q2 2026.
  • BlackRock bought 2,000,796 Myriad Genetics shares in Q2 2026, an estimated $9.08M.
  • Myriad Genetics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2533 holding.
  • BlackRock first reported a position in Myriad Genetics in Q2 2013 and has held it in 53 quarters since.
  • BlackRock's Myriad Genetics position peaked at $527M in Q3 2018.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.